Methods and compositions for preventing and treating a disease related to glycan dysregulation
AssigneesThe Regents of the University of California, Mount Sinai Hospital
InventorsMichael Demetriou, James Dennis, Ken Siu-Kwong Lau
Life of this patent
Estimating the term…
Abstract
Contemplated compositions and methods are directed to prevent and/or treat various autoimmune diseases that are typically associated with glycan dysregulation, and especially autoimmune demyelinating diseases. Further especially contemplated aspects include animal models and systems for screening compounds to treat and/or prevent such diseases.
Claims19
A method for treating insulin-dependent diabetes mellitus comprising administering to a subject having insulin-dependent diabetes mellitus a therapeutically effective amount of at least one of (a) a sugar donor for Mgat5, (b) an agonist for Mgat5, and (c) a metabolite, regulator, or an agonist of a pathway for synthesis of a sugar donor for Mgat5, wherein the level of Mgat5 modified glycans is increased in the subject, thereby treating the subject's insulin-dependent diabetes mellitus.
A method of treating insulin-dependent diabetes mellitus comprising administering to a subject having insulin-dependent diabetes mellitus a therapeutically effective amount of a metabolite of a pathway for synthesis of a sugar donor for Mgat5 wherein said metabolite is GlcNAc or a nutraceutically acceptable derivative thereof, wherein the level of Mgat5 modified glycans is increased in the subject, thereby treating the subject's insulin-dependent diabetes mellitus.
A method of treating insulin-dependent diabetes mellitus comprising administering to a subject having insulin-dependent diabetes mellitus a nutraceutical or pharmaceutical composition comprising GlcNAc or a nutraceutically acceptable derivative thereof, and uridine, uridine 5′ diphosphate (UDP), uridine 5′ monophosphate (UMP), uridine 5′ triphosphate (UTP), uracil, or a nutraceutically acceptable derivative thereof, and a pharmaceutically acceptable or nutraceutically acceptable carrier.
Dependencies are inferred from the claim text.